0.6175  0.006 (0.95%)		10-04 10:35
Open: 0.611 High: 0.6286 Volume: 18,439		Pre. Close: 0.6117 Low: 0.61 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	1.59	1-year :	2.17
Resists	First :	1.36	Second :	1.86
Pivot price	0.68
Supports	First :	0.56	Second :	0.47
MAs	MA(5) :	0.61	MA(20) :	0.78
	MA(100) :	2.45	MA(250) :	8.29
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	9.4	D(3) :	8.8
RSI	RSI(14): 28.2
52-week	High :	20.15	Low :	0.56

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PRFX ] has closed above bottom band by 31.1%. Bollinger Bands are 65.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.64 - 0.65	0.65 - 0.65
Low:	0.59 - 0.6	0.6 - 0.6
Close:	0.6 - 0.61	0.61 - 0.62

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Wed, 18 Sep 2024
PRFX stock touches 52-week low at $0.74 amid sharp annual decline - Investing.com

Wed, 11 Sep 2024
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewswire

Tue, 10 Sep 2024
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewswire

Tue, 10 Sep 2024
PainReform to issue new warrants in stock exercise deal - Investing.com

Tue, 10 Sep 2024
PRFX stock touches 52-week low at $1.17 amid steep annual decline - Investing.com

Tue, 10 Sep 2024
PainReform Shares Are Trading Lower Today: What's Going On - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	6.6 (%)
Held by Institutions	8.9 (%)
Shares Short	65 (K)
Shares Short P.Month	13 (K)

EPS	-36.85
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-3.53
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-195.1 %
Return on Equity (ttm)	-716.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.99
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.02
PEG Ratio	0
Price to Book value	-0.18
Price to Sales	0
Price to Cash Flow	-0.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.